Drug Trial Radar · NCT05494918
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors
Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Sep 2, 2022
Primary completion
Apr 15, 2025
Study completion Apr 15, 2025
Sponsor
- Lead sponsor
- Alphamab (Australia) Co Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter, first-in-human, Phase I, dose escalation study to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of JSKN003 in subjects with advanced inoperable or metastatic solid malignant tumors that are expected to be HER2 expression.
Conditions
- Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
JSKN003Drug
JSKN003 is to be administered via intravenous (IV) dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: Postdose of last participant up to 1 year
- Preliminary RDE/RP2DTime frame: Postdose of last participant up to 1 year
- DLTsTime frame: Baseline up to 21 days after the first dose
- Adverse EventsTime frame: Baseline up to 30 days after the last dose of study drug, up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast Cancer Research Centre
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.